Neonatal Fc Receptor Blockers [MoA] - N0000194005

Pharmacologic Code	N0000194005
Pharmacologic Name	Neonatal Fc Receptor Blockers
Pharmacologic Uses	neonatal Fc receptor blocker
Pharmacologic Concept	Mechanisms of Action - [MoA]
Pharmacologic Concept Description	This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept.

The table contains 7 products whose active ingredient are classified under the same pharmacologic class Neonatal Fc Receptor Blockers [MoA].

	NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
	50474-980	Rystiggo	Non-Proprietary Name: Rozanolixizumab	Injection, Solution	Subcutaneous	Ucb, Inc.	ACTIVE
	50474-981	Rystiggo	Non-Proprietary Name: Rozanolixizumab	Injection, Solution	Subcutaneous	Ucb, Inc.	ACTIVE
	50474-982	Rystiggo	Non-Proprietary Name: Rozanolixizumab	Injection, Solution	Subcutaneous	Ucb, Inc.	ACTIVE
	50474-983	Rystiggo	Non-Proprietary Name: Rozanolixizumab	Injection, Solution	Subcutaneous	Ucb, Inc.	ACTIVE
	73475-1221	Vyvgart Hytrulo	Non-Proprietary Name: Efgartigimod Alfa And Hyaluronidase (human Recombinant)	Injection, Solution	Subcutaneous	Argenx Us	ACTIVE
	73475-3041	Vyvgart	Non-Proprietary Name: Efgartigimod Alfa	Injection	Intravenous	Argenx Us	ACTIVE
	73475-3102	Vyvgart Hytrulo	Non-Proprietary Name: Efgartigimod Alfa And Hyaluronidase (human Recombinant)	Injection, Solution	Subcutaneous	Argenx Us	ACTIVE